Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance

被引：11
作者：
Duda-Madej, Anna [1 ]
Viscardi, Szymon [2 ]
Topola, Ewa [2 ]
机构：
[1] Wroclaw Med Univ, Fac Med, Dept Microbiol, Chalubinskiego 4, PL-50368 Wroclaw, Poland
[2] Wroclaw Med Univ, Fac Med, Ludw Pasteura 1, PL-50367 Wroclaw, Poland
来源：
ANTIBIOTICS-BASEL | 2023年 / 12卷 / 11期
关键词：
beta-lactam/beta-lactamase inhibitor; carbapenem-resistant Enterobacterales (CRE); Klebsiella pneumoniae carbapenemase (KPC); meropenem; multidrug resistance; vaborbactam; URINARY-TRACT-INFECTION; MEROPENEM-VABORBACTAM; ENTEROBACTERIACEAE; RPX7009; PREVENTION; PNEUMONIA; STABILITY;
D O I：
10.3390/antibiotics12111612
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Due to the fact that there is a steadily increasing trend in the area of antimicrobial resistance in microorganisms, there is a need to look for new treatment alternatives. One of them is the search for new beta-lactamase inhibitors and combining them with beta-lactam antibiotics, with the aim of increasing the low-dose efficacy, as well as lowering the resistance potential of bacterial strains. This review presents the positive effect of meropenem in combination with a vaborbactam (MER-VAB). This latest antibiotic-inhibitor combination has found particular use in the treatment of infections with the etiology of carbapenem-resistant Enterobacterales (CRE), Gram-negative bacteria, with a high degree of resistance to available antimicrobial drugs.
引用
收藏
页数：17
相关论文
共 74 条
  • [1] Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections
    Ackley, Renee
    Roshdy, Danya
    Meredith, Jacqueline
    Minor, Sarah
    Anderson, William E.
    Capraro, Gerald A.
    Polk, Christopher
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (05)
  • [2] Antibiotic Resistance during COVID-19: A Systematic Review
    Al Sulayyim, Hadi Jaber
    Ismail, Rohani
    Al Hamid, Abdullah
    Ghafar, Noraini Abdul
    [J]. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (19)
  • [3] Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa
    Alosaimy, Sara
    Lagnf, Abdalhamid M.
    Morrisette, Taylor
    Scipione, Marco R.
    Zhao, Jing J.
    Jorgensen, Sarah C. J.
    Mynatt, Ryan
    Carlson, Travis J.
    Jo, Jinhee
    Garey, Kevin W.
    Allen, David
    DeRonde, Kailynn
    Vega, Ana D.
    Abbo, Lilian M.
    Venugopalan, Veena
    Athans, Vasilios
    Saw, Stephen
    Claeys, Kimberly C.
    Miller, Mathew
    Molina, Kyle C.
    Veve, Michael
    Kufel, Wesley D.
    Amaya, Lee
    Yost, Christine
    Ortwine, Jessica
    Davis, Susan L.
    Rybak, Michael J.
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (08):
  • [4] Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections
    Alosaimy, Sara
    Jorgensen, Sarah C. J.
    Lagnf, Abdalhamid M.
    Melvin, Sarah
    Mynatt, Ryan P.
    Carlson, Travis J.
    Garey, Kevin W.
    Allen, David
    Venugopalan, Veena
    Veve, Michael
    Athans, Vasilios
    Saw, Stephen
    Yost, Christine N.
    Davis, Susan L.
    Rybak, Michael J.
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (03):
  • [5] Andrei Stefan, 2018, Discoveries (Craiova), V6, pe81, DOI 10.15190/d.2018.1
  • [6] Meropenem/Vaborbactam Plus Aztreonam as a Possible Treatment Strategy for Bloodstream Infections Caused by Ceftazidime/Avibactam-Resistant Klebsiella pneumoniae: A Retrospective Case Series and Literature Review
    Belati, Alessandra
    Bavaro, Davide Fiore
    Diella, Lucia
    De Gennaro, Nicolo
    Di Gennaro, Francesco
    Saracino, Annalisa
    [J]. ANTIBIOTICS-BASEL, 2022, 11 (03):
  • [7] Exploring Aztreonam in Combination with Ceftazidime-Avibactam or Meropenem-Vaborbactam as Potential Treatments for Metallo- and Serine-β-Lactamase-Producing Enterobacteriaceae
    Biagi, M.
    Wu, T.
    Lee, M.
    Patel, S.
    Butler, D.
    Wenzler, E.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (12)
  • [8] Epidemiology and In Vitro Activity of Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam against KPC-Producing K. pneumoniae Collected from Bacteremic Patients, 2018 to 2020
    Bovo, Federica
    Lombardo, Donatella
    Lazzarotto, Tiziana
    Ambretti, Simone
    Gaibani, Paolo
    [J]. ANTIBIOTICS-BASEL, 2022, 11 (11):
  • [9] Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It
    Breijyeh, Zeinab
    Jubeh, Buthaina
    Karaman, Rafik
    [J]. MOLECULES, 2020, 25 (06):
  • [10] Global antibiotic consumption and usage in humans, 2000-18: a spatial modelling study
    Browne, Annie J.
    Chipeta, Michael G.
    Haines-Woodhouse, Georgina
    Kumaran, Emmanuelle P. A.
    Hamadani, Bahar H. Kashef
    Zaraa, Sabra
    Henry, Nathaniel J.
    Deshpande, Aniruddha
    Reiner, Robert C., Jr.
    Day, Nicholas P. J.
    Lopez, Alan D.
    Dunachie, Susanna
    Moore, Catrin E.
    Stergachis, Andy
    Hay, Simon, I
    Dolecek, Christiane
    [J]. LANCET PLANETARY HEALTH, 2021, 5 (12) : E893 - E904
12345678